Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Friday, 13'th Dec 2024
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
04:30pm, Thursday, 12'th Dec 2024
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, at the Westin St. Francis in San Fran
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
02:23pm, Thursday, 12'th Dec 2024
It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others.
The 3 Highest Yielding Dogs of the Dow Are December Holiday Bargains
06:18am, Wednesday, 11'th Dec 2024
The Dow Jones industrial average is a price-weighted average of 30 blue-chip U.S.
Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends
03:42pm, Tuesday, 10'th Dec 2024
"Dividend Aristocrats
Johnson & Johnson Just Paid Investors: Here's How Much They Received
10:15am, Tuesday, 10'th Dec 2024
Johnson & Johnson (NYSE: JNJ) is rewarding its shareholders once again with a quarterly dividend of $1.24, payable on Tuesday, Dec.
89 percent of patients evaluable for MRD assessment were MRD negative, with the majority reaching MRD negativity in less than 2 months Results add to the overall survival (OS) benefits recently pres
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
04:15pm, Monday, 09'th Dec 2024
PARIS and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanopartic
ChatGPT-4o builds an ideal $1,000 stock portfolio for the first half of 2025
10:01am, Monday, 09'th Dec 2024
The new year presents another opportunity for investors to stake a claim in select companies that show growth potential.
Three CEOs That Ought to Follow Intel's Pat Gelsinger Out the Door
09:54am, Monday, 09'th Dec 2024
Intel (NASDAQ:INTC) CEO Pat Gelsinger stepped down on Dec.
Abstracts presented at ASH 2024 provide insight into the patient experience given the unpredictable nature of wAIHA, a rare autoantibody disease, and the uncertainty of current treatment approaches us
New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10 -6) with DARZALEX FASPRO ® were progression free at 4.5 years Subgroup analysis from Phas
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy SAN DIEGO , Dec. 8, 2024 /
First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study
5 Relatively Secure And Cheap Dividend Stocks For December 2024: Yields Up To 9%
09:00am, Saturday, 07'th Dec 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter
